Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
52 hedge funds and large institutions have $29.7M invested in Cidara Therapeutics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 8 closing their positions.
2,567% more call options, than puts
Call options by funds: $80K | Put options by funds: $3K
64% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 11
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.06% less ownership
Funds ownership: 1.52% → 1.46% (-0.06%)
4% less funds holding
Funds holding: 54 → 52 (-2)
14% less capital invested
Capital invested by funds: $34.4M → $29.7M (-$4.75M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$377K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$353K |
| 3 |
Renaissance Technologies
New York
|
+$344K |
| 4 |
BlackRock
New York
|
+$259K |
| 5 |
Morgan Stanley
New York
|
+$220K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.19M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$902K |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$545K |
| 4 |
Jane Street
New York
|
-$389K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$94.3K |
CDTX Hedge Fund Activity: Q2 2023 in Review
52 of the 6,382 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2023, worth a combined $29.7M — down 14% from $34.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CDTX and 6 opened new positions — a net loss of 2 holders — while 11 trimmed existing stakes and 18 added.
The largest buyer was Connor, Clark & Lunn Investment Management (CC&L), opening a new position worth an estimated $377K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.19M sold.
- 52 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2023, down from 54 in Q1 2023.
- Funds reported $29.7M of Cidara Therapeutics stock for Q2 2023, down 14% quarter-over-quarter.
- 6 funds opened new Cidara Therapeutics positions in Q2 2023 and 8 closed out, a net change of -2 holders.
- The largest Cidara Therapeutics buyer in Q2 2023 was Connor, Clark & Lunn Investment Management (CC&L), an estimated $377K added.
- The largest Cidara Therapeutics seller in Q2 2023 was Acadian Asset Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q2 2023.